Upadacitinib patent?

What is the current status of the upadacitinib patent?

Upadacitinib is a medication used to treat rheumatoid arthritis, Crohn's disease, and ulcerative colitis. The medication is developed by AbbVie, and the company has secured patents for the compound worldwide.

According to DrugPatentWatch.com [1], the original patent for upadacitinib (ABT-494) was filed in 2008 and granted in 2014. The patent covers the compound and its use in treating certain inflammatory diseases.

When does the upadacitinib patent expire?

The patent for upadacitinib in the United States is set to expire on 2027, with the drug's exclusivity period ending in 2030 [1]. Similar patent expirations are expected in other countries, although the exact dates may vary.

How does the patent expiration impact AbbVie?

The expiration of the upadacitinib patent will likely allow generic manufacturers to produce and market their versions of the medication. However, AbbVie has a range of strategies in place to mitigate the impact of generic competition, including developing additional indications for the drug and building a strong pipeline of new products.

What are the implications for patients and healthcare providers?

Once the patent expires, it's likely that the cost of upadacitinib will decrease as generic versions become available. Patients may have more affordable access to the medication, although they should consult with their healthcare providers to determine the best treatment option for their individual needs.

Sources:

[1] DrugPatentWatch.com - Upadacitinib (ABT-494) Patent Information